Blood Safety for Africa

An Opportunity to Help

Although the resource-constrained African region does not represent a significant commercial opportunity, it certainly represents a human opportunity. It is also an opportunity for Cerus to share its depth of experience and expertise in pathogen inactivation with African communities. Cerus, together with the University Hospitals of Geneva (HUG) and their Blood Transfusion Center (CTS), and the Transfusion Service of the Swiss Red Cross (Transfusion CRS Suisse), is committed to helping make pathogen inactivation a reality in Africa, by exploring ways to adapt the INTERCEPT Blood System (S-303) for Red Cells, for use in whole blood.

The Need for Safe Blood in Africa
Africa Map
  • The majority of blood transfusions in Africa are provided to pregnant women and to children, with children receiving more than any other patient group.
  • Only ~40% of the demand for transfusions is currently being met in Africa.
  • >500,000 maternal deaths occur each year worldwide, the majority of which are in sub-Saharan Africa, where postpartum hemorrhage is the leading cause of maternal death.
  • Transfusion-transmitted infections are prevalent in local African blood donors, contributing to transmission-related infections to patients and restrictions and shortages for blood supply.

Securing Transfusion Safety Around the Globe

In developed countries, patients receive transfusions of individual blood components, either platelets, plasma or red blood cells, or a combination of these components. Cerus’ INTERCEPT Blood System for pathogen inactivation is currently being used to treat platelets and plasma to reduce the risk of transfusion-related infections. The company’s program for red blood cells, which is currently in clinical development, is designed to complete the pathogen inactivation capability for all three blood components regularly transfused in the developed world.

But geographies like Africa present a very different challenge in transfusion medicine: namely, given the lack of appropriate resources and technology, whole blood transfusion– as opposed to blood components - is most frequently used to treat patients. Africa in particular is also faced with additional challenges to its blood supply, including shortages in available blood and elevated risks of transfusion-transmitted infections. These blood supply challenges can have devastating tolls on human health.



The Transfusion Service of the Swiss Red Cross (Blutspende SRK Schwietz)

Cerus Corporation

Interested in contributing to this collaboration?
Please contact us for further details.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600